A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections.
A consortium of life sciences companies including pharma giants such as Novartis and Johnson & Johnson, are to collaborate to develop and manufacture vaccines, diagnostics and treatment
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh